Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pBTE-Fc
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intrathecal
01
Overview
pBTE-Fc is a recombinant bispecific T-cell engager (BTE) fusion protein containing an Fc region, designed to target the tumor-associated antigen interleukin-13 receptor alpha 2 (IL13Rα2). It is utilized in a novel immunotherapeutic strategy where naïve T cells are pre-complexed with the BTE (pBTE) prior to intrathecal delivery. This approach aims to treat central nervous system (CNS) malignancies, such as glioblastoma (GBM) and leptomeningeal disease (LMD), by bypassing the blood-tumor and blood-CSF barriers. The Fc fusion construct is designed to improve the retention and stability of the engager on the T-cell surface, enhancing its anti-tumor activity within the immunologically cold tumor microenvironment of the CNS.
- Other names
- IL13Rα2-specific BTE-Fc fusion constructpre-complexed bispecific T-cell engager-Fc
02
Targets
C1Q (Complement C1q)CD3 (T-cell surface glycoprotein CD3)FCGRT (Neonatal crystallizable fragment receptor)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)IL13RA2 (Interleukin-13 receptor subunit alpha 2)
Beyond the preview
Go deeper on pBTE-Fc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pBTE-Fc.